# Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance

> **NCT03227926** · PHASE2 · COMPLETED · sponsor: **Fondazione del Piemonte per l'Oncologia** · enrollment: 32 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]
- **DIAGNOSTIC_TEST:** Molecular Screening

## Key facts

- **NCT ID:** NCT03227926
- **Lead sponsor:** Fondazione del Piemonte per l'Oncologia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-11
- **Primary completion:** 2019-11-06
- **Final completion:** 2021-12-31
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03227926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03227926, "Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03227926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*